跳轉至內容
Merck
全部照片(2)

Key Documents

CLL1135

Sigma-Aldrich

SKOV3 Cells GFP-HER2

登入查看組織和合約定價


About This Item

分類程式碼代碼:
41106514
NACRES:
NA.81

生物源

human female ovary (Source Disease: Ovarian adenocarcinoma)

品質等級

OMIM登錄號

儲存溫度

−196°C

基因資訊

一般說明

SKOV3 GFP-HER2 are ovarian adenocarcinoma cells from a human 64 year old caucasion female having a ZFN modification creating a HER2-GFP transgene expressed from the endogenous HER2 gene locus.

This cell line was derived from ATCC Catalog No. HTB-77.

應用

SKOV3 Cells GFP-HER2 has been used for live-cell screening assays to find compounds that affect cell structure or signaling pathways.
This product is a human SKOV3 cell line in which the genomic HER2 gene has been endogenously tagged with a Green Fluorescent Protein (GFP) gene using CompoZr® Zinc Finger Nuclease technology. Integration resulted in endogenous expression of the fusion protein in which GFP is attached to the C-terminus of HER2. Fluorescence imaging shows characteristic HER2 membrane expression. This stable cell line was expanded from a single clone. The target′s gene regulation and corresponding protein function are preserved in contrast to cell lines with overexpression via an exogenous promoter.

To learn more, please visit the Cellular Reporter Cell Line webpage

生化/生理作用

Human epidermal growth factor receptor 2 (HER2) signaling pathway promotes cell proliferation and survival in majority of breast cancers. Thus, overexpression of this protein leads to breast cancer. Heterodimeric complex of HER2 and phosphatidylinositide 3-kinase (PI3K) is the most potent stimulator of the phosphatidylinositol-3-kinase (PI3K)/Akt anti-apoptosis pathway. Upregulated expression of HER2 is associated with the development of ovarian, colorectal, pancreatic, endometrial and gastric cancers. Trastuzumab, an antibody, works by binding to a domain in the external domain of HER2. This domain is missing in p95, a truncated form of HER2, and hence these cancer cells show resistance to trastuzumab. HER2 protein can be used as a prognostic marker and as a therapeutic option for gynecologic cancers.

特點和優勢

Zinc Finger Nuclease (ZFN)-mediated targeted integration of a fluorescent GFP tag into the last exon of the HER2 gene on chromosome 17q21.1 to create a cell line exhibiting stable expression of the transgene tagged with GFP on the C-terminus of the protein.

The SKOV3 cells are adherent, with a doubling time of approx. 48 hours.

品質

Tested for Mycoplasma, sterility, post-freeze viability, short terminal repeat (STR) analysis for cell line identification, cytochrome oxidase I (COI) analysis for cell line species confirmation.

準備報告

Media Renewal changes two to three times per week.

Rapidly thaw vial by gentle agitation in 37°C water bath (~2 minutes), keeping vial cap out of the water. Decontaminate with 70% ethanol, add 9 mL culture media and centrifuge 125 x g (5-7 minutes). Resuspend in complete culture media and incubate at 37°C in a 5% CO2 atmosphere.

Subculture Ratio: approx. 1:3-1:6

The base medium for this cell line is McCoy′s 5A Medium, Cat. No. M8403. To make the complete growth medium, add the following components to the base medium: fetal bovine serum, Cat. No. F2442, to a final concentration (v/v) of 10% and L-glutamine, Cat. No. G7513, at a final concentration of 1.5 mM.

Cell freezing medium-DMSO 1X, Cat. No. C6164.

法律資訊

CompoZr is a registered trademark of Merck KGaA, Darmstadt, Germany

免責聲明

RESEARCH USE ONLY. This product is regulated in France when intended to be used for scientific purposes, including for import and export activities (Article L 1211-1 paragraph 2 of the Public Health Code). The purchaser (i.e. enduser) is required to obtain an import authorization from the France Ministry of Research referred in the Article L1245-5-1 II. of Public Health Code. By ordering this product, you are confirming that you have obtained the proper import authorization.

分析證明 (COA)

輸入產品批次/批號來搜索 分析證明 (COA)。在產品’s標籤上找到批次和批號,寫有 ‘Lot’或‘Batch’.。

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

HER2 expression beyond breast cancer: therapeutic implications for gynecologic malignancies.
English DP, et al.
Molecular Diagnosis & Therapy, 17(2), 85-99 (2013)
The role of p95HER2 in trastuzumab resistance in breast cancer.
Ozkavruk Eliyatkin N, et al.
Journal of B.U.ON. : Official Journal of the Balkan Union of Oncology, 21(2), 382-389 (2016)
HER2: biology, detection, and clinical implications.
Gutierrez C and Schiff R.
Archives of Pathology & Laboratory Medicine, 135(1), 55-62 (2011)

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務